Management of chronic nonbacterial prostatitis/chronic pelvic pain syndrome
Chronic nonbacterial prostatitis/chronic pelvic pain syndrome is unsatisfactorily defined and insufficiently studied illness. Also, the treatment success is questionable and therefore, this illness is a therapeutical problem for urologists--which medications are the best choice in treating this unco...
Gespeichert in:
| Veröffentlicht in: | Biomolecules & biomedicine 2007-08, Vol.7 (3), p.245-249 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 249 |
|---|---|
| container_issue | 3 |
| container_start_page | 245 |
| container_title | Biomolecules & biomedicine |
| container_volume | 7 |
| creator | Kulovac, Benjamin Aganović, Damir Prcić, Alden Hadziosmanović, Osman |
| description | Chronic nonbacterial prostatitis/chronic pelvic pain syndrome is unsatisfactorily defined and insufficiently studied illness. Also, the treatment success is questionable and therefore, this illness is a therapeutical problem for urologists--which medications are the best choice in treating this uncomfortable condition? This paper presents results of prospective, open, analytical, comparative study that was performed on 90 patients with diagnosed chronic nonbacterial prostatitis/chronic pelvic pain syndrome. Patients were divided into three groups and were treated with two medications ciprofloxacin (C), doxazosin (D) and combination of ciprofloxacin + doxazosin (C+D). The effects were measured using symptom questionnaire for prostate illnesses of the National Institute for Health - USA (NIH-CPSI). During the basic evaluation, sum ranging from 0 to 43 was calculated for each patient. This number is called total sum NIH-CPSI (National Institutes of Health Chronic Prostatitis Symptom Index) of the questionnaire, which generates the questions from 1 to 9. The most significant change occurred in C+D group where the total sum changed from 18-38 in the beginning to 5-31 at the end of the treatment (55,1% (p |
| doi_str_mv | 10.17305/bjbms.2007.3053 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5736117</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_6fe2a00a99ca4617a33c9ff13363e946</doaj_id><sourcerecordid>68259662</sourcerecordid><originalsourceid>FETCH-LOGICAL-c418t-96cb804deef0827c534678a75db53a43f6eee7f50800036487b1254af42958c93</originalsourceid><addsrcrecordid>eNpVkctv1DAQhy0EomXhzgnlxC1bO35fkFBVoKKIC5ytiTPeepXYi52t1P-e7INHT-PHbz5b8xHyltE105zKq37bT3XdUarXy5Y_I5fMCNoKw7rny1qyrjWKsgvyqtYtpcpyI16SC6bNEpHsknz9Bgk2OGGamxwaf19yir5JOfXgZywRxmZXcp1hjnOsV38COxwfDgViaupjGkqe8DV5EWCs-OZcV-Tnp5sf11_au--fb68_3rVeMDO3VvneUDEgBmo67SUXShvQcuglB8GDQkQdJDWUUq6E0T3rpIAgOiuNt3xFbk_cIcPW7UqcoDy6DNEdD3LZOChz9CM6FbADSsFaD0IxDZx7GwLjXHG0Qi2sDyfWbt9POPhlDgXGJ9CnNyneu01-cFJzxRYJK_L-DCj51x7r7KZYPY4jJMz76pTppFWqW4L0FPTLOGvB8PcRRt3RpjvadAeb7mBzaXn3_-f-NZz18d9BuJ0W</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>68259662</pqid></control><display><type>article</type><title>Management of chronic nonbacterial prostatitis/chronic pelvic pain syndrome</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Kulovac, Benjamin ; Aganović, Damir ; Prcić, Alden ; Hadziosmanović, Osman</creator><creatorcontrib>Kulovac, Benjamin ; Aganović, Damir ; Prcić, Alden ; Hadziosmanović, Osman</creatorcontrib><description>Chronic nonbacterial prostatitis/chronic pelvic pain syndrome is unsatisfactorily defined and insufficiently studied illness. Also, the treatment success is questionable and therefore, this illness is a therapeutical problem for urologists--which medications are the best choice in treating this uncomfortable condition? This paper presents results of prospective, open, analytical, comparative study that was performed on 90 patients with diagnosed chronic nonbacterial prostatitis/chronic pelvic pain syndrome. Patients were divided into three groups and were treated with two medications ciprofloxacin (C), doxazosin (D) and combination of ciprofloxacin + doxazosin (C+D). The effects were measured using symptom questionnaire for prostate illnesses of the National Institute for Health - USA (NIH-CPSI). During the basic evaluation, sum ranging from 0 to 43 was calculated for each patient. This number is called total sum NIH-CPSI (National Institutes of Health Chronic Prostatitis Symptom Index) of the questionnaire, which generates the questions from 1 to 9. The most significant change occurred in C+D group where the total sum changed from 18-38 in the beginning to 5-31 at the end of the treatment (55,1% (p<0,001)). Significant changes were also found in D group where the change was 46, 4% (p<0,001). At the end of the treatment no significant change was registered in C group (p<0,005): p<0,001--significance threshold. Combination of ciprofloxacin + doxazosin proved to be the best choice for treatment.</description><identifier>ISSN: 1512-8601</identifier><identifier>ISSN: 2831-0896</identifier><identifier>EISSN: 1840-4812</identifier><identifier>EISSN: 2831-090X</identifier><identifier>DOI: 10.17305/bjbms.2007.3053</identifier><identifier>PMID: 17848151</identifier><language>eng</language><publisher>Bosnia and Herzegovina: Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina</publisher><subject>Adult ; Anti-Infective Agents - therapeutic use ; Chronic Disease ; chronic nonbacterial prostatitis/chronic pelvic pain syndrome ; Ciprofloxacin - therapeutic use ; Doxazosin - therapeutic use ; Drug Therapy, Combination ; Humans ; Male ; Middle Aged ; Pelvic Pain - diagnosis ; Pelvic Pain - therapy ; Prospective Studies ; Prostatic Diseases - drug therapy ; Prostatitis - diagnosis ; Prostatitis - pathology ; Surveys and Questionnaires ; therapy ; Vasodilator Agents - therapeutic use</subject><ispartof>Biomolecules & biomedicine, 2007-08, Vol.7 (3), p.245-249</ispartof><rights>Copyright: © 2007 ABMSFBIH 2007</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c418t-96cb804deef0827c534678a75db53a43f6eee7f50800036487b1254af42958c93</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5736117/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5736117/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17848151$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kulovac, Benjamin</creatorcontrib><creatorcontrib>Aganović, Damir</creatorcontrib><creatorcontrib>Prcić, Alden</creatorcontrib><creatorcontrib>Hadziosmanović, Osman</creatorcontrib><title>Management of chronic nonbacterial prostatitis/chronic pelvic pain syndrome</title><title>Biomolecules & biomedicine</title><addtitle>Bosn J Basic Med Sci</addtitle><description>Chronic nonbacterial prostatitis/chronic pelvic pain syndrome is unsatisfactorily defined and insufficiently studied illness. Also, the treatment success is questionable and therefore, this illness is a therapeutical problem for urologists--which medications are the best choice in treating this uncomfortable condition? This paper presents results of prospective, open, analytical, comparative study that was performed on 90 patients with diagnosed chronic nonbacterial prostatitis/chronic pelvic pain syndrome. Patients were divided into three groups and were treated with two medications ciprofloxacin (C), doxazosin (D) and combination of ciprofloxacin + doxazosin (C+D). The effects were measured using symptom questionnaire for prostate illnesses of the National Institute for Health - USA (NIH-CPSI). During the basic evaluation, sum ranging from 0 to 43 was calculated for each patient. This number is called total sum NIH-CPSI (National Institutes of Health Chronic Prostatitis Symptom Index) of the questionnaire, which generates the questions from 1 to 9. The most significant change occurred in C+D group where the total sum changed from 18-38 in the beginning to 5-31 at the end of the treatment (55,1% (p<0,001)). Significant changes were also found in D group where the change was 46, 4% (p<0,001). At the end of the treatment no significant change was registered in C group (p<0,005): p<0,001--significance threshold. Combination of ciprofloxacin + doxazosin proved to be the best choice for treatment.</description><subject>Adult</subject><subject>Anti-Infective Agents - therapeutic use</subject><subject>Chronic Disease</subject><subject>chronic nonbacterial prostatitis/chronic pelvic pain syndrome</subject><subject>Ciprofloxacin - therapeutic use</subject><subject>Doxazosin - therapeutic use</subject><subject>Drug Therapy, Combination</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Pelvic Pain - diagnosis</subject><subject>Pelvic Pain - therapy</subject><subject>Prospective Studies</subject><subject>Prostatic Diseases - drug therapy</subject><subject>Prostatitis - diagnosis</subject><subject>Prostatitis - pathology</subject><subject>Surveys and Questionnaires</subject><subject>therapy</subject><subject>Vasodilator Agents - therapeutic use</subject><issn>1512-8601</issn><issn>2831-0896</issn><issn>1840-4812</issn><issn>2831-090X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>DOA</sourceid><recordid>eNpVkctv1DAQhy0EomXhzgnlxC1bO35fkFBVoKKIC5ytiTPeepXYi52t1P-e7INHT-PHbz5b8xHyltE105zKq37bT3XdUarXy5Y_I5fMCNoKw7rny1qyrjWKsgvyqtYtpcpyI16SC6bNEpHsknz9Bgk2OGGamxwaf19yir5JOfXgZywRxmZXcp1hjnOsV38COxwfDgViaupjGkqe8DV5EWCs-OZcV-Tnp5sf11_au--fb68_3rVeMDO3VvneUDEgBmo67SUXShvQcuglB8GDQkQdJDWUUq6E0T3rpIAgOiuNt3xFbk_cIcPW7UqcoDy6DNEdD3LZOChz9CM6FbADSsFaD0IxDZx7GwLjXHG0Qi2sDyfWbt9POPhlDgXGJ9CnNyneu01-cFJzxRYJK_L-DCj51x7r7KZYPY4jJMz76pTppFWqW4L0FPTLOGvB8PcRRt3RpjvadAeb7mBzaXn3_-f-NZz18d9BuJ0W</recordid><startdate>20070801</startdate><enddate>20070801</enddate><creator>Kulovac, Benjamin</creator><creator>Aganović, Damir</creator><creator>Prcić, Alden</creator><creator>Hadziosmanović, Osman</creator><general>Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20070801</creationdate><title>Management of chronic nonbacterial prostatitis/chronic pelvic pain syndrome</title><author>Kulovac, Benjamin ; Aganović, Damir ; Prcić, Alden ; Hadziosmanović, Osman</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c418t-96cb804deef0827c534678a75db53a43f6eee7f50800036487b1254af42958c93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Adult</topic><topic>Anti-Infective Agents - therapeutic use</topic><topic>Chronic Disease</topic><topic>chronic nonbacterial prostatitis/chronic pelvic pain syndrome</topic><topic>Ciprofloxacin - therapeutic use</topic><topic>Doxazosin - therapeutic use</topic><topic>Drug Therapy, Combination</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Pelvic Pain - diagnosis</topic><topic>Pelvic Pain - therapy</topic><topic>Prospective Studies</topic><topic>Prostatic Diseases - drug therapy</topic><topic>Prostatitis - diagnosis</topic><topic>Prostatitis - pathology</topic><topic>Surveys and Questionnaires</topic><topic>therapy</topic><topic>Vasodilator Agents - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kulovac, Benjamin</creatorcontrib><creatorcontrib>Aganović, Damir</creatorcontrib><creatorcontrib>Prcić, Alden</creatorcontrib><creatorcontrib>Hadziosmanović, Osman</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Biomolecules & biomedicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kulovac, Benjamin</au><au>Aganović, Damir</au><au>Prcić, Alden</au><au>Hadziosmanović, Osman</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Management of chronic nonbacterial prostatitis/chronic pelvic pain syndrome</atitle><jtitle>Biomolecules & biomedicine</jtitle><addtitle>Bosn J Basic Med Sci</addtitle><date>2007-08-01</date><risdate>2007</risdate><volume>7</volume><issue>3</issue><spage>245</spage><epage>249</epage><pages>245-249</pages><issn>1512-8601</issn><issn>2831-0896</issn><eissn>1840-4812</eissn><eissn>2831-090X</eissn><abstract>Chronic nonbacterial prostatitis/chronic pelvic pain syndrome is unsatisfactorily defined and insufficiently studied illness. Also, the treatment success is questionable and therefore, this illness is a therapeutical problem for urologists--which medications are the best choice in treating this uncomfortable condition? This paper presents results of prospective, open, analytical, comparative study that was performed on 90 patients with diagnosed chronic nonbacterial prostatitis/chronic pelvic pain syndrome. Patients were divided into three groups and were treated with two medications ciprofloxacin (C), doxazosin (D) and combination of ciprofloxacin + doxazosin (C+D). The effects were measured using symptom questionnaire for prostate illnesses of the National Institute for Health - USA (NIH-CPSI). During the basic evaluation, sum ranging from 0 to 43 was calculated for each patient. This number is called total sum NIH-CPSI (National Institutes of Health Chronic Prostatitis Symptom Index) of the questionnaire, which generates the questions from 1 to 9. The most significant change occurred in C+D group where the total sum changed from 18-38 in the beginning to 5-31 at the end of the treatment (55,1% (p<0,001)). Significant changes were also found in D group where the change was 46, 4% (p<0,001). At the end of the treatment no significant change was registered in C group (p<0,005): p<0,001--significance threshold. Combination of ciprofloxacin + doxazosin proved to be the best choice for treatment.</abstract><cop>Bosnia and Herzegovina</cop><pub>Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina</pub><pmid>17848151</pmid><doi>10.17305/bjbms.2007.3053</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1512-8601 |
| ispartof | Biomolecules & biomedicine, 2007-08, Vol.7 (3), p.245-249 |
| issn | 1512-8601 2831-0896 1840-4812 2831-090X |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5736117 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Adult Anti-Infective Agents - therapeutic use Chronic Disease chronic nonbacterial prostatitis/chronic pelvic pain syndrome Ciprofloxacin - therapeutic use Doxazosin - therapeutic use Drug Therapy, Combination Humans Male Middle Aged Pelvic Pain - diagnosis Pelvic Pain - therapy Prospective Studies Prostatic Diseases - drug therapy Prostatitis - diagnosis Prostatitis - pathology Surveys and Questionnaires therapy Vasodilator Agents - therapeutic use |
| title | Management of chronic nonbacterial prostatitis/chronic pelvic pain syndrome |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-19T14%3A42%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Management%20of%20chronic%20nonbacterial%20prostatitis/chronic%20pelvic%20pain%20syndrome&rft.jtitle=Biomolecules%20&%20biomedicine&rft.au=Kulovac,%20Benjamin&rft.date=2007-08-01&rft.volume=7&rft.issue=3&rft.spage=245&rft.epage=249&rft.pages=245-249&rft.issn=1512-8601&rft.eissn=1840-4812&rft_id=info:doi/10.17305/bjbms.2007.3053&rft_dat=%3Cproquest_doaj_%3E68259662%3C/proquest_doaj_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=68259662&rft_id=info:pmid/17848151&rft_doaj_id=oai_doaj_org_article_6fe2a00a99ca4617a33c9ff13363e946&rfr_iscdi=true |